T细胞免疫与肺癌
本综述聚焦T细胞在肺癌抗肿瘤免疫中的核心作用,总结近期进展。肿瘤特异性CD8+ T细胞直接攻击肿瘤细胞但慢性抗原刺激导致功能耗竭;调节性T细胞通过多种抑制机制影响临床结局;肿瘤内三级淋巴结构可放大局部免疫并与疗效和预后相关;肿瘤微环境代谢特征调节T细胞分化与持久性。
要点
- 肿瘤特异性CD8+ T细胞是抗肿瘤免疫核心,但慢性抗原刺激导致功能耗竭限制治疗反应。
- 调节性T细胞通过多种抑制机制调节免疫反应并影响临床结局。
- 肿瘤内三级淋巴结构可放大局部免疫,与疗效和预后相关。
核心结论
- 阐明T细胞功能状态对优化肺癌免疫治疗和实现持久获益至关重要。
研究设计与样本
- 综述,聚焦T细胞在肺癌中的作用并总结近期进展。
主要发现
- 肿瘤特异性CD8+ T细胞直接攻击肿瘤细胞,但慢性抗原刺激驱动功能受损和耗竭,限制治疗反应性。
- 调节性T细胞通过多样抑制机制调节免疫反应并影响临床结局。
- 肿瘤内三级淋巴结构通过滤泡辅助T细胞、B细胞及其他免疫亚群间相互作用放大局部免疫,日益与治疗疗效和预后相关。
- 新证据表明肿瘤微环境代谢特征调节T细胞分化与持久性。
临床怎么用
- 上述见解为将T细胞中心免疫反应及其调控回路的理解转化为临床实践提供基础。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lung cancer remains a leading cause of cancer mortality worldwide. Although immune checkpoint inhibitors (ICIs) have reshaped therapeutic strategies in lung cancer, their benefits remain limited. ICIs exert their therapeutic efficacy by activating T-cell effector functions, underscoring the central role of T cells in antitumor immunity. Thus, this review focuses on the role of T cells in lung cancer and summarises recent advances. Tumour-specific CD8+ T cells that attack tumour cells directly form the core of antitumor immunity, yet chronic antigenic stimulation drives functional impairment and exhaustion that constrain treatment responsiveness. Conversely, regulatory T cells modulate immune responses through diverse suppressive mechanisms and influence clinical outcomes. In addition, tertiary lymphoid structures (TLSs) that arise within tumours can amplify local immunity through interactions among follicular helper T cells, B cells, and other immune subsets, and are increasingly linked to therapeutic efficacy and prognosis. Emerging evidence also indicates that metabolic features of the tumour microenvironment modulate T-cell differentiation and persistence. Collectively, these insights provide a foundation for translating an improved understanding of T-cell-centred immune responses and their regulatory circuits into clinical practice. Overall, clarifying T-cell functional states is essential for optimising immunotherapy and achieving durable benefit in lung cancer.
引用
- Yamada K, Togashi Y. T-Cell Immunity and Lung Cancer. Respirology. 2026. PMID: 41669970. doi:10.1002/resp.70220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。